Notably, Favipiravir is currently the only oral anti-viral treatment approved in various countries for the potential treatment of patients with mild to moderate Covid-19 disease.
Ramesh Krishnamurthy, CEO of Vivimed Labs Ltd said, "With over 300,000 Covid-19 cases being reported daily thought out the world, there is an urgent need to provide more treatment options to healthcare professionals. We are launching "Favulous" at an economical price to make the drug accessible to more and more patients thereby ensuring good health and reducing their financial burden. This is in line with our continuous efforts to support the world's pandemic response".
Further, Vivimed said, "We expect to receive further repeat orders during the Year".
On Sensex, the Vivimed stock was trading at the upper circuit band of Rs12.84 per piece, up by 4.99% at around 11.31 am.